Gefitinib Completed Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00130702Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia